I agree with many of the posters that the current share price...

I agree with many of the posters that the current share price undervalues the Relenza royalties and give no value to the potential of LANI.

However some posters should take caution to speculate the potential of China or Chinese manufacturers making money for BTA shareholders.

These posters should take an interest at this article (and many other similar news)and gauge for themselves how hard GSK had been trying to market Relenza and or producing Relenza.

http://www.chinadaily.com.cn/bizchina/2009-02/06/content_7450505.htm